Polyneuropatie indukovaná chemoterapií

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Chemotherapy-induced polyneuropathy
Authors

RAPUTOVÁ Jana VLČKOVÁ Eva ŠMARDOVÁ Lenka RAJDOVÁ Aneta JANÍKOVÁ Andrea

Year of publication 2017
Type Article in Periodical
Magazine / Source Neurologie pro praxi
MU Faculty or unit

Faculty of Medicine

Citation
Field Neurology, neurosurgery, neurosciences
Keywords polyneuropathies; antineoplastic agents; cisplatin; taxoids; vinca alkaloids; proteasome inhibitors
Description Chemotherapy-induced polyneuropathy belongs to frequent adverse effects of anticancer chemotherapy with a significant negative influence on patients` daily living and social activities. Neuropathy is axonal, affects large and/or small nerve fibers (based on particular drug) and causes sensory, motor and/or autonomic symptoms and signs. The most important neurotoxic agents are platinum derivatives, taxoids, vinca alkaloids, thalidomide and proteasome inhibitors. CIPN is usually at least partly reversible, however, some drugs can damage nerve fibres irreversibly, e.g. thalidomid. CIPN prevention is mainly based on appropriate indication of neurotoxic drugs considering preexisting polyneuropathy and its risk factors. If the polyneuropathy occurs during the anticancer treatment, dose reduction or change of anticancer treatment can prevent further worsening of the peripheral nerve impairment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.